Market Currents
RXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3...
-
Monday, September 12, 2011, 11:41 AM ETRXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3 clinical trial of NeuVax, a cancer immunotherapy targeted for breast cancer patients not eligible for other treatment.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
